PET-designed treatment lowers risk of drug abuse

Article

PET imaging of the brain demonstrates that a slow-release formula of a drug used to treat attention-deficit/hyperactivity disorder is as effective as a rapid-release version and less likely to be abused.

PET imaging of the brain demonstrates that a slow-release formula of a drug used to treat attention-deficit/hyperactivity disorder is as effective as a rapid-release version and less likely to be abused.

Dr. Thomas J. Spencer, assistant director of the pediatric psychopharmacology unit at Massachusetts General Hospital, and colleagues used carbon-11 altropane PET to investigate a new once-a-day capsule developed to slowly release methylphenidate.

The drug boosts dopamine activity in the frontal cortex and improves the ability to pay attention. But it may also lead to patient abuse.

The researchers evaluated 12 healthy adults randomly assigned to receive immediate-release or osmotic-release methylphenidate. PET showed that the 90-mg osmotic-release capsule produced the same effects as 40 mg of immediate-release methylphenidate. They reported their results in the March American Journal of Psychiatry.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.